Navigation Links
China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
Date:4/17/2009

TAIAN CITY, China, April 17 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), announced that it has completed the third installment payment towards the acquisition of a 90% equity interest in Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") for a total consideration of RMB 194,400,000 (approximately $28.5 million), in accordance with the terms of an equity transfer agreement with the Dalin shareholders, and is now entitled to all the rights and privileges of a 90% shareholder in Dalin and in Dalin's 54% majority-owned operating subsidiary, Qianfeng Biological Products Co., Ltd. ("Qianfeng"), one of the largest plasma-based biopharmaceutical companies in China, located in Guiyang, Guizhou Province.

This installment represents the Company's payment of an aggregate 90% of the total purchase price, and according to the equity transfer agreement, as amended, Logic Holding (Hong Kong) Limited ("Logic Holding"), the Company's wholly-owned subsidiary, is now entitled to all the rights and privileges of a 90% shareholder in Dalin, including the right to receive its pro rata share of 54% of the profits generated by Qianfeng, as of January 1, 2009, subject to a possible dilution to as low as 41.3%, if a dissenting Qianfeng shareholder prevails in a pre-existing suit to obtain additional equity interests in Qianfeng.

On March 26, 2009, Dalin received a certificate of approval from the municipal government in Chongqing for the establishment of a Taiwan, Hong Kong, Macao and Overseas Chinese invested enterprise in China, which allows Dalin to operate as a Sino-foreign joint venture; and on April 10, 2009, Dalin, as a Sino-foreign joint venture, received business licenses from the Chongqing City Administration for Industry and Commerce
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results
3. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
4. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
5. China Agri-Business Announces 2008 Operating Results
6. China Biologic Products Announces Strong 2008 Results
7. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
8. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
9. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
10. aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
11. Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences announced ... research and development agreement (CRADA) with Aratana Therapeutics ... development of TRB-N0224 for the treatment and control ... and cats.  Traverse Biosciences has also granted Aratana ... treatment and control of periodontal disease in companion ...
(Date:5/4/2015)... /PRNewswire/ - The Fight Against Cancer Innovation Trust ... the formation of Turnstone Biologics Inc. (Turnstone), a ... that harness the patient,s own immune system. ... the Children,s Hospital of Eastern Ontario ... Ontario Institute for Cancer Research (OICR), the Ottawa ...
(Date:5/4/2015)... MA (PRWEB) May 04, 2015 ... for drug discovery and life science research, today ... , the latest version of its enterprise solution ... biopharma R&D enables more efficient discovery and development ... approach to integrate and address protein optimization and ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) ... products that address unmet medical needs in the areas ... will be presenting preclinical data from three of its ... Science and Technology Conference on May 12-14, 2015 to ... 701 Convention Plaza, St. Louis MO ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12
... GLASGOW, Scotland, Sept. 3 Leading neurosurgical ... in neurosurgical,diagnostic and treatment devices, along with ... and efficient at the European,Association of Neurosurgical ... than 1,000 neurosurgeons and related medical professionals,will ...
... PARIS, September 2 Sanofi-aventis announced,today that ... 25 and STEEPLE,studies confirm clear net clinical ... infarction (STEMI) for Lovenox(R) vs,Unfractionnated Heparin (UFH). ... year results were presented during,hotline sessions at ...
... Standards and Technology (NIST) have developed two ... validate the performance of analytic instruments that ... Recent years have seen a significant increase ... analytic techniques. Researchers can detect, measure and ...
Cached Biology Technology:Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 2New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 3New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 4New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome 5Fluorescent glass SRMs are new tool for spectroscopy 2
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications ... a global provider of Software Defined Network Architecture (ET ... announced total revenue of approximately $20.4 million for the ... restated $19.5 million for the year ended December 31, ... 2014, the Company had completed its multi-year transition away ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... designated FV-100, which could alleviate the suffering of millions of ... stage of clinical testing in patients. Developed and ... clinical trial with FV-100 has recently been initiated in America. ... to 10,000 times more potent than existing treatments in early ...
... international team of scientists has proposed a set of ... reefs from ultimate destruction. Their proposal is being ... Indonesia, where leaders of six regional governments plus Australia ... largest-ever marine reserve in world history, the Coral Triangle ...
... the world,s second largest fish hide out for ... online on May 7th in Current Biology , ... of the iconic species and highlights just how little ... animals, the researchers said. "While commonly sighted in ...
Cached Biology News:Clinical trials for shingles drug take an important step forward 2Rules proposed to save the world's coral reefs 2Rules proposed to save the world's coral reefs 3Disappearing act of world's second largest fish explained 2
... L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, veterinary and experimental ... 3 minutes after turn-on. ... ... ...
Human/Mouse/Rat LAR Affinity Purified PAb...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
APG5 autophagy 5-like (S. cerevisiae)...
Biology Products: